Year All202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 05, 2024 Read More BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones Feb 26, 2024 Read More BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment Feb 23, 2024 Read More BioCryst to Present at Upcoming Investor Conferences Feb 21, 2024 Read More BioCryst Launches ORLADEYO® (berotralstat) in Italy Feb 19, 2024 Read More BioCryst to Report Fourth Quarter 2023 Financial Results on February 26 Feb 12, 2024 Read More BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting Feb 05, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 02, 2024 Read More BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability Jan 05, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 03, 2024 Read More
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones Feb 26, 2024 Read More
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment Feb 23, 2024 Read More
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting Feb 05, 2024 Read More
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability Jan 05, 2024 Read More